Semaglutide in Adolescents Living With Obesity: A Real-World Data Study Exploring Predictors of Treatment Response.
Semaglutide isn’t just for adults. A new real-world data study from the UK dives into how adolescents with obesity respond to this GLP-1 research peptide. Researchers at Southampton Children’s Hospital tracked teens using semaglutide and dug into which factors actually predict results.
Diabetes Obes Metab
by Cimador V, Robertson S, Desmond C et al.
“Semaglutide in Adolescents Living With Obesity: A Real-World Data Study Exploring Predictors of Treatment Response. Cimador V(1)(2), Robertson S(3), Desmond C(1), Dodgson J(3), van Boxel E(1), Davis NL(1), Moon RJ(1)(4)(5). Author information: (1)Regional Centre for Paediatric Endocrinology, Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, UK. (2)Residency School of Pediatrics, University of Bologna, Bologna, Italy. (3)Department of Paediatrics, Portsmouth Hospitals University NHS Trust, Portsmouth, UK. (4)MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK. (5)NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.”
The standout: response to semaglutide in adolescents is highly individual. Some teens dropped significant weight, others saw modest changes. The team looked for patterns—age, sex, starting BMI, and even behavioral factors. No single trait guaranteed a strong result, but a few trends emerged.
Key takeaways:
Teens with higher initial BMI often saw greater absolute weight loss (makes sense: more to lose, more can be lost).
No big difference in response between boys and girls.
Early weight loss (in the first 3 months) was a decent sign that a teen would keep losing.
Ongoing lifestyle support—diet, activity, monitoring—worked alongside semaglutide for best results.
This matters for research. Real-world data is messy, but it’s honest. Trials show what happens in perfect conditions. This study shows what happens in clinics, with real people, unpredictable lives, and all the usual chaos.
If you’re researching semaglutide or similar GLP-1 peptides in adolescents, this is gold. Predictors matter. Early responders might be worth extra focus, and BMI could help stratify research groups.
Want to see more details or source semaglutide for your own studies? Check out the semaglutide page or browse the vendor directory for sourcing options.
Real-world data like this keeps peptide research grounded—and interesting.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.